---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116327"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:36:05.870096+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Armata completes enrollment of Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia; topline Q1 2025

## Summary
- Full enrollment (n=50) achieved for intravenous AP-SA02 in Phase 1b/2a diSArm study targeting Staphylococcus aureus bacteremia.
- Topline data expected in Q1 2025; if positive, may support initiation of a pivotal efficacy trial later in 2025.
- Dose escalated to 5E10 PFU every 6 hours (2E11 PFU/24h) for 5 days without clinically significant adverse events.
- Two blinded subsets observed: one showing evidence of in vivo phage amplification with detectable phage in blood.
- Study supported by $21.6M in funding from Defense Health Agency and Joint Warfighter Medical Research Program via MTEC and NMRC-NAMD.

## SEC filing metadata
- accession: 0001104659-24-116327
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465924116327/0001104659-24-116327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465924116327/tm2428148d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116327
- JSON: https://secwatch.observer/filing/0001104659-24-116327.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116327.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.